InsidersTradesSigma
Total declarations
Company
▲ Purchases (29 ops.)
▼ Sales (1 ops.)
Insider track record
OtherDisclosed buys
29
Disclosed sells
1
T+90 hit rate
0%
T+90 mean return
-46.4%
Across 29 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the full record of transactions filed by Aquilo Capital Management, LLC. Officer active across 1 company, notably Spero Therapeutics, Inc.. In total, 30 filings have been recorded. Breakdown: 29 buys · 1 sell. Total volume traded: €28.4m. Activity tracked since 20 August 2021. The latest transaction was disclosed on 22 September 2022 (Cession). Regulator: SEC (Form 4). All data is openly available.
Declarations30 total
1,335,512 shares@ US$2.250310.7% of flowCommon Stock, $0.001 par valueSEC:0001591986-22-000018:0
39,727 shares@ US$5.2350.15% mcap0.8% of flowCommon Stock, $0.001 par valueSEC:0001591986-22-000015:0
Ideal exit: 21 Jan 2023 (T+270)
33,115 shares@ US$8.78840.20% mcap1.0% of flowCommon Stock, $0.001 par valueSEC:0001591986-22-000014:0
Ideal exit: 25 Dec 2022 (T+270)
15,702 shares@ US$7.6260.083% mcap0.4% of flowCommon Stock, $0.001 par valueSEC:0001591986-22-000013:0
Ideal exit: 9 Dec 2022 (T+270)
29,729 shares@ US$9.52930.19% mcap1.0% of flowCommon Stock, $0.001 par valueSEC:0001591986-22-000011:0
Ideal exit: 25 Nov 2022 (T+270)
14,828 shares@ US$9.24190.092% mcap0.5% of flowCommon Stock, $0.001 par valueSEC:0001591986-22-000010:0
Ideal exit: 15 Nov 2022 (T+270)
125,000 shares@ US$11.58614.6% of flowCommon Stock, $0.001 par valueSEC:0001591986-22-000004
Ideal exit: 28 Oct 2022 (T+270)
125,000 shares@ US$11.58610.99% mcap5.1% of flowCommon Stock, $0.001 par valueSEC:0001591986-22-000004:0
Ideal exit: 28 Oct 2022 (T+270)
1,599 shares@ US$10.89310.012% mcap0.1% of flowCommon Stock, $0.001 par valueSEC:0001591986-22-000003:0
Ideal exit: 21 Oct 2022 (T+270)
1,599 shares@ US$10.89310.1% of flowCommon Stock, $0.001 par valueSEC:0001591986-22-000003
Ideal exit: 21 Oct 2022 (T+270)
48,488 shares@ US$12.41471.9% of flowCommon Stock, $0.001 par valueSEC:0001591986-22-000002
Ideal exit: 15 Oct 2022 (T+270)
48,488 shares@ US$12.41470.40% mcap2.1% of flowCommon Stock, $0.001 par valueSEC:0001591986-22-000002:0
Ideal exit: 15 Oct 2022 (T+270)
8,867 shares@ US$12.92530.077% mcap0.4% of flowCommon Stock, $0.001 par valueSEC:0001591986-22-000001:0
Ideal exit: 7 Oct 2022 (T+270)
8,867 shares@ US$12.92530.4% of flowCommon Stock, $0.001 par valueSEC:0001591986-22-000001
Ideal exit: 7 Oct 2022 (T+270)
75,493 shares@ US$14.64063.4% of flowCommon Stock, $0.001 par valueSEC:0001691902-22-000001
Ideal exit: 25 Sept 2022 (T+270)
75,493 shares@ US$14.64060.74% mcap3.8% of flowCommon Stock, $0.001 par valueSEC:0001691902-22-000001:0
Ideal exit: 25 Sept 2022 (T+270)
150,000 shares@ US$17.53451.71% mcap8.9% of flowCommon Stock, $0.001 par valueSEC:0001591986-21-000016:0
Ideal exit: 26 Jul 2022 (T+270)
150,000 shares@ US$17.53457.9% of flowCommon Stock, $0.001 par valueSEC:0001591986-21-000016
Ideal exit: 26 Jul 2022 (T+270)
134,543 shares@ US$18.64961.65% mcap8.5% of flowCommon Stock, $0.001 par valueSEC:0001591986-21-000015:0
Ideal exit: 27 Jun 2022 (T+270)
134,543 shares@ US$18.64967.6% of flowCommon Stock, $0.001 par valueSEC:0001591986-21-000015
Ideal exit: 27 Jun 2022 (T+270)
44,210 shares@ US$18.56310.53% mcap2.7% of flowCommon Stock, $0.001 par valueSEC:0001591986-21-000014:0
Ideal exit: 10 Jun 2022 (T+270)
44,210 shares@ US$18.56312.4% of flowCommon Stock, $0.001 par valueSEC:0001591986-21-000014
Ideal exit: 10 Jun 2022 (T+270)
24,749 shares@ US$18.49740.29% mcap1.5% of flowCommon Stock, $0.001 par valueSEC:0001591986-21-000013:0
Ideal exit: 6 Jun 2022 (T+270)
24,749 shares@ US$18.49741.4% of flowCommon Stock, $0.001 par valueSEC:0001591986-21-000013
Ideal exit: 6 Jun 2022 (T+270)
44,042 shares@ US$17.86610.51% mcap2.6% of flowCommon Stock, $0.001 par valueSEC:0001591986-21-000012:0
Ideal exit: 27 May 2022 (T+270)
25 of 30 declarations
About Aquilo Capital Management, LLC
Aquilo Capital Management, LLC is a significant shareholder of Spero Therapeutics, Inc.
